🟠 Moderate Evidence
A new study published in Otolaryngology–Head and Neck Surgery reports that gepants—a class of oral and intranasal medications—demonstrate efficacy and tolerability in treating vestibular migraine (VM), a condition that combines migraine headaches with balance and dizziness symptoms. The findings suggest gepants may expand treatment options for patients with this disabling condition.
Key takeaways
- Gepants, calcitonin gene-related peptide (CGRP) antagonists, show effectiveness in managing vestibular migraine symptoms
- Both oral and intranasal formulations demonstrate tolerability in treatment protocols
- The finding expands the therapeutic armamentarium for a condition that significantly impacts quality of life
Study at a Glance
| Source | Otolaryngology–Head and Neck Surgery |
| Study type | Clinical trial / observational analysis |
| Drug class | Gepants (CGRP antagonists) |
| Condition | Vestibular migraine (VM) |
| Formulations tested | Oral and intranasal |
Gepants Expand VM Treatment Options
Therapeutic mechanisms and formulation routes now available for vestibular migraine management
Source: Otolaryngology–Head and Neck Surgery, 2026 | Georgian Medical Journal News
What are gepants and how do they work?
Gepants are small-molecule antagonists of the calcitonin gene-related peptide (CGRP) receptor, a mechanism of action that has gained prominence in migraine therapeutics over the past decade. These medications block CGRP, a neuropeptide implicated in migraine pathophysiology, thereby reducing the cascade of neuroinflammatory events that trigger migraine attacks. According to research from the National Institute of Neurological Disorders and Stroke (NINDS), CGRP-targeted therapies have demonstrated efficacy across multiple migraine phenotypes.
The availability of both oral and intranasal formulations offers clinicians flexibility in prescribing. Oral gepants provide sustained therapeutic levels for prophylactic use, while intranasal formulations enable rapid onset during acute migraine episodes. This dual-route approach aligns with personalized medicine principles, allowing treatment selection based on individual patient needs and migraine pattern. For more on clinical updates in migraine management, see related coverage.
Vestibular migraine: a common yet underrecognized condition
Vestibular migraine affects a substantial proportion of the migraine-affected population, yet remains underdiagnosed and undertreated compared to other migraine subtypes. The condition is characterized by recurrent episodes of dizziness, vertigo, or imbalance occurring in temporal association with migraine headaches, visual symptoms, or migraine-related sensitivities. According to the American Headache Society criteria, vestibular migraine can significantly impair occupational and social functioning.
Current treatment approaches for VM have relied primarily on traditional migraine medications (beta-blockers, tricyclic antidepressants, topiramate) that were not specifically designed for vestibular symptoms. The availability of CGRP-targeted therapies offers a mechanistically distinct option. Research published in peer-reviewed otolaryngology journals suggests that up to 30% of patients with chronic dizziness have an underlying migraine mechanism, underscoring the clinical importance of accurate diagnosis and targeted treatment. See our patient health resources for additional information on vestibular conditions.
Gepants represent a novel therapeutic class specifically targeting the CGRP pathway implicated in vestibular migraine pathophysiology, offering both efficacy and tolerability advantages over older non-specific migraine therapies.
— Study findings, Otolaryngology–Head and Neck Surgery, 2026
Clinical implications and patient access considerations
The efficacy and tolerability profile of gepants in vestibular migraine opens new treatment pathways for patients who have failed or poorly tolerated conventional prophylactic agents. The ability to use intranasal formulations for acute treatment addresses a critical gap in VM management, as patients often experience rapid symptom onset that benefits from quick-acting interventions. According to guidance from the U.S. Food and Drug Administration, several gepants have received approval for migraine indication, though vestibular migraine-specific labeling may require additional clinical evidence.
However, access and reimbursement remain challenges in many healthcare systems. Gepants are relatively newer medications and may face prior authorization requirements or formulary restrictions. Clinicians managing patients with refractory vestibular migraine should engage with insurance and health system formulary committees to advocate for appropriate access, particularly in cases where older agents have proven ineffective. Explore more on pharmacy and prescribing guidance for related coverage of medication access issues.
What this means
Frequently asked questions
What is the difference between vestibular migraine and regular migraine?
Vestibular migraine is a migraine subtype in which patients experience dizziness, vertigo, or balance problems occurring alongside or instead of headache. Regular migraine may not involve vestibular symptoms. According to criteria published in neurology and otolaryngology literature, vestibular symptoms must occur at least half the time and last from seconds to days to meet diagnostic criteria for VM.
How quickly do intranasal gepants work compared to oral formulations?
Intranasal gepants typically achieve therapeutic concentrations within 30–60 minutes due to rapid mucosal absorption, making them suitable for acute migraine treatment. Oral formulations require 1–2 hours for peak effect but provide sustained levels suitable for preventive use. The choice depends on whether the medication is being used for acute symptom relief or ongoing migraine prevention.
Are there any safety concerns with long-term gepant use?
The safety profile of gepants has been favourable in clinical trials published in major neurology and headache journals, with adverse events generally mild and comparable to placebo in most populations. However, as with all medications, individual patient factors and drug interactions should be assessed by a clinician. Patients should report any unusual symptoms to their healthcare provider.
The emergence of gepants as an effective and well-tolerated option for vestibular migraine reflects broader progress in understanding and targeting migraine biology. As real-world evidence accumulates and healthcare systems integrate these newer agents into clinical pathways, patients with this common yet often underrecognized condition will benefit from expanded and more effective therapeutic options. Continued research into vestibular-specific outcomes and long-term efficacy will further refine treatment algorithms for this population.
Source: Common dizziness drug class shows promise for treating vestibular migraine
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
